Drug Trial Radar · NCT06559007
Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants
Last checked: Nov 20, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 25, 2024
Primary completion
Jan 6, 2025
Study completion Mar 3, 2025
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, open-label, randomized study. The objective of this study is to evaluate the PK, safety and tolerability of orally administered single-dose HRS-5041 in healthy Caucasian male participants.
Conditions
- Prostate Cancer
Interventions
HRS-5041 dose level 1Drug
Single dose of HRS-5041 orally administered
HRS-5041 dose level 2Drug
Single dose of HRS-5041 orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK profile (Cmax) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
- PK profile (AUC0-t) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
- PK profile (AUC0-inf) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
- PK profile (Tmax) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
- PK profile ( t1/2) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
- PK profile (CL/F) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
- PK profile (Vz/F) of HRS-5041 after a single oral (PO) administration:Time frame: Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Melbourne
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.